199 related articles for article (PubMed ID: 36319945)
1. Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis.
Domingo C; Fernandez M; Garin N; Milara J; Moran I; Muerza I; Pacheco A; Teruel C; Bentley R; Subiran R; Gil A
Appl Health Econ Health Policy; 2023 Jan; 21(1):119-130. PubMed ID: 36319945
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis.
Bali V; Schelfhout J; Sher MR; Tripathi Peters A; Patel GB; Mayorga M; Goss D; Romano CD
Ther Adv Respir Dis; 2024; 18():17534666241236025. PubMed ID: 38501735
[TBL] [Abstract][Full Text] [Related]
3. Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA).
Falip M; López González FJ; Martín-Herranz I; Merino-Bohórquez V; Montoya J; Rey Gómez-Serranillos I; Rodriguez Uranga JJ; Ruiz E; Sancho-López A; Trillo Mata JL; Antoni Vallès J; Álvarez-Barón E; Sabaniego J; Subías-Labazuy S; Gil A
Epilepsy Behav; 2023 Aug; 145():109350. PubMed ID: 37480633
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Management of Patients with Refractory or Unexplained Chronic Cough in Outpatient Hospital Clinics in Spain: A Retrospective Multicenter Study.
Dávila I; Puente L; Quirce S; Arismendi E; Díaz-Palacios M; Pereira-Vega A; de Diego A; Rodriguez-Hermosa JL; Cea-Calvo L; Sánchez-Jareño M; López-Cotarelo P; Domingo C
Lung; 2023 Jun; 201(3):275-286. PubMed ID: 37160771
[TBL] [Abstract][Full Text] [Related]
5. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
[TBL] [Abstract][Full Text] [Related]
6. Speech and language therapy for management of chronic cough.
Slinger C; Mehdi SB; Milan SJ; Dodd S; Matthews J; Vyas A; Marsden PA
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD013067. PubMed ID: 31335963
[TBL] [Abstract][Full Text] [Related]
7. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
[TBL] [Abstract][Full Text] [Related]
8. A register-based study: cough - a frequent phenomenon in the adult population.
Backer V; Porsborg A; Hansen V; Skjold T; Schmid JM; Kehlet M; Torp-Pedersen C; Aasbjerg K
BMC Pulm Med; 2022 Nov; 22(1):426. PubMed ID: 36401236
[TBL] [Abstract][Full Text] [Related]
9. Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough.
Nguyen AM; Schelfhout J; Muccino D; Bacci ED; La Rosa C; Vernon M; Birring SS
Ther Adv Respir Dis; 2022; 16():17534666221099737. PubMed ID: 35614875
[TBL] [Abstract][Full Text] [Related]
10. Understanding physician's knowledge and perception of chronic cough in Switzerland.
Leuppi JD; Guggisberg P; Koch D; Favre-Bulle A; Fabiani M; Heinz S; Zeller A
Curr Med Res Opin; 2022 Aug; 38(8):1459-1466. PubMed ID: 35369836
[TBL] [Abstract][Full Text] [Related]
11. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
12. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
Dicpinigaitis PV; Birring SS; Blaiss M; McGarvey LP; Morice AH; Pavord ID; Satia I; Smith JA; La Rosa C; Li Q; Nguyen AM; Schelfhout J; Tzontcheva A; Muccino D
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):60-66. PubMed ID: 35569802
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review of treatments used for refractory or unexplained chronic cough in adults.
Bali V; Kardos P; Page C; Rogliani P; Calzetta L; Adriano A; Byrne A; Adeyemi A; Frederickson A; Schelfhout J
Ann Thorac Med; 2024; 19(1):56-73. PubMed ID: 38444993
[TBL] [Abstract][Full Text] [Related]
14. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
Jiménez A; Ais A; Beaudet A; Gil A
Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
[TBL] [Abstract][Full Text] [Related]
15. Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.
Martin Nguyen A; Bacci E; Dicpinigaitis P; Vernon M
Ther Adv Respir Dis; 2020; 14():1753466620915155. PubMed ID: 32345170
[TBL] [Abstract][Full Text] [Related]
16. New Insights Into Refractory Chronic Cough and Unexplained Chronic Cough: A 6-Year Ambispective Cohort Study.
Zhang M; Morice AH; Si F; Zhang L; Chen Q; Wang S; Zhu Y; Xu X; Yu L; Qiu Z
Allergy Asthma Immunol Res; 2023 Nov; 15(6):795-811. PubMed ID: 37957796
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough.
Mazzone SB; McGarvey L
Clin Pharmacol Ther; 2021 Mar; 109(3):619-636. PubMed ID: 32748976
[TBL] [Abstract][Full Text] [Related]
18. The Severity of Chronic Cough Diary (SCCD): development and content validation of a novel patient-reported outcome instrument for evaluating the symptom experience of chronic cough.
de la Orden Abad M; Haberland C; Karn H; Skalicky A; Hareendran A
J Patient Rep Outcomes; 2023 Jul; 7(1):65. PubMed ID: 37428359
[TBL] [Abstract][Full Text] [Related]
19. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs in the treatment of chronic cough.
Brister D; Wahab M; Rashad M; Diab N; Kolb M; Satia I
Expert Opin Emerg Drugs; 2023 Dec; 28(2):67-77. PubMed ID: 37060576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
